Home › Chronic Lymphocytic Leukemia › Virginia
Pag-aaral pangklinika para sa Chronic Lymphocytic Leukemia sa Virginia
12 pag-aaral para sa Chronic Lymphocytic Leukemia ang naghahanap ng mga kalahok sa mga site sa Virginia.
Mga Lungsod sa Virginia
Opisyal na teksto ng pag-aaral (English)
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Ballad Health Cancer Care - Bristol, Bristol
- Ballad Health Cancer Care - Norton, Norton
- VCU Massey Cancer Center at Stony Point, Richmond
- at 1 pa
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 12, 2026 · NCT04269902A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
- University of Virginia Cancer Center ( Site 5402), Charlottesville
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 6, 2026 · NCT05947851A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- USO-Virginia Oncology Associates, Hampton
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 4, 2026 · NCT06588478Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Chesapeake Regional Medical Center, Chesapeake
- Augusta Health Center for Cancer and Blood Disorders, Fishersville
- Bon Secours Memorial Regional Medical Center, Mechanicsville
- at 7 pa
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 40 hanggang 75 · Lahat ng kasarian · Na-update Nob 4, 2026 · NCT05334069Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
- VCU Massey Comprehensive Cancer Center, Richmond
- VCU Health Tappahannock Hospital, Tappahannock
Nagre-recruitPhase 3
Edad 65 pataas · Lahat ng kasarian · Na-update Nob 3, 2026 · NCT07321652A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- University of Virginia Medical Center, Charlottesville
- Virginia Cancer Specialists, PC, Fairfax
- Oncology & Hematology Associates of Southwest VA, Norfolk
- at 1 pa
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 3, 2026 · NCT07221500A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- University of Virginia Cancer Center ( Site 0040), Charlottesville
- Inova Schar Cancer Institute ( Site 0015), Fairfax
- Virginia Commonwealth University (VCU) Medical Center ( Site 0030), Richmond
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 13, 2026 · NCT06136559A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Virginia Commonwealth University Massey Cancer Center, Richmond
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 5, 2026 · NCT05006716A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Blue Ridge Cancer Care (Oncology and Hematology Associates of Southwest Virginia), Roanake
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT06973187Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
- Virginia Cancer Specialists, Fairfax
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 31, 2026 · NCT07516093A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Virginia Cancer Institute, Richmond
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 17, 2026 · NCT05254743A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
- Virginia Cancer Specialists - Fairfax /ID# 268155, Fairfax
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 9, 2026 · NCT06428019Mula sa ClinicalTrials.gov, na-kuha noong Nob 15, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.